Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co (300937) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co (300937) currently trades at ¥20.77, while our model-based Fair Value estimate is ¥8.73 — implying the stock looks roughly 58.0% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It is involved in pharmaceutical B2B e-commerce, production, wholesale, and retail businesses, as well as provides logistics services. It offers Western medicine, Chinese patent medicine, Chinese herbal medicine slices and Chinese medicinal materials, food and health food, medical devices and non-pharmaceuticals, and other categories. The company also provides clinics, E-commerce platform operation, logistics and distribution, management consulting, warehousing, property management, drug sale and retail chain, technology promotion and application, internet hospital, other organizational management, new media operation, equipment sales, and software development services, and information technology services, as well as engages in medical research and experimental development. The company was founded in 2007 and is based in Chengdu, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co (300937) undervalued?
What is the fair value of 300937?
What is the quality score of 300937?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.